Collegium (COLL) Q2 2026: ADHD Portfolio Revenue Jumps 41% as Astaris Integration Accelerates Diversification
Collegium’s ADHD franchise delivered outsized growth, with Jornay PM revenue up 41% and Astaris now integrated, setting up a pivotal back-to-school season. Pain portfolio durability continues to fund expansion, but authorized generic pricing pressure on Nucynta weighs on the outlook. Management’s capital deployment remains disciplined, with a clear bias toward CNS and rare disease asset acquisitions in the near term.
Summary
- ADHD Franchise Expansion: Jornay PM and Astaris drive portfolio diversification and growth momentum.
- Pain Business Stability: Core pain assets fund innovation, but Nucynta generics pressure revenue mix.
- Strategic M&A Focus: Management signals continued disciplined capital deployment into CNS and rare disease.
Business Overview
Collegium Pharmaceutical develops and commercializes medicines for complex central nervous system (CNS) and pain conditions, with a focus on innovative formulation and delivery. The company’s revenue is anchored by two major segments: a growing ADHD franchise (Jornay PM and Astaris) and an established pain management portfolio (Belbuca, Xtampza, Nucynta). Collegium generates revenue through direct product sales, profit-sharing on authorized generics, and leverages its commercial infrastructure to integrate acquired assets.
Performance Analysis
Collegium delivered 6% top-line growth in Q2, driven by a 41% surge in Jornay PM revenue and initial contributions from Astaris following its May acquisition. ADHD net revenues now represent a rapidly expanding share of the business, with Jornay PM prescriptions up 13.1% and prescribers up 17.6% year-over-year. Astaris added $12.9 million in partial-quarter revenue, reflecting both organic demand and early integration success. The back-to-school season is expected to amplify this momentum as the sales force, now fully trained on both products, targets expanded healthcare provider (HCP) lists.
The pain portfolio remains a critical cash generator, with Belbuca up 10% year-over-year and securing new formulary access for 9 million additional lives in Q4. However, Nucynta franchise revenue fell 24% year-over-year, pressured by steep net price declines in authorized generics, now stabilizing at 10-15% of branded IR and 20-25% of branded ER pricing. Xtampza ER also declined, facing tough comps and broader branded opioid market headwinds. Operating cash flow remains robust, enabling continued investment and M&A activity.
- ADHD Outperformance: Jornay PM and Astaris combined are reshaping revenue mix, with strong HCP adoption and differentiated product positioning.
- Pain Portfolio Margin: Belbuca’s resilience and new access offsetting generic erosion in Nucynta, but overall pain revenues are pressured.
- Cost Structure Shift: Operating expenses climbed 45% on acquisition charges, but adjusted SG&A is up only 8%, reflecting disciplined investment.
Collegium’s model is increasingly reliant on ADHD growth and efficient portfolio integration, while pain assets provide the financial backbone for continued diversification.
Executive Commentary
"This latest acquisition further reinforces the strategy we initiated in 2024 to diversify our portfolio beyond responsible pain management and establish a strong presence in the growing ADHD market."
Vikram Karnani, President and Chief Executive Officer
"We are updating our 2026 financial guidance primarily to reflect lower-than-expected full-year revenue for the Nucynta franchise due to lower net pricing for the authorized generics. Importantly, our revenue expectations for Jornay remain unchanged, with guidance of $190 to $200 million."
Colleen Tupper, Chief Financial Officer
Strategic Positioning
1. ADHD Franchise as Growth Engine
Collegium’s ADHD business is now the company’s primary growth lever, with Jornay PM and Astaris offering differentiated profiles for distinct patient needs. Market research shows HCPs rate Jornay PM as the most differentiated branded ADHD medicine, with 70% of surveyed prescribers intending to increase use. The acquisition of Astaris extends the ADHD portfolio lifecycle (IP protection to 2037) and leverages existing commercial infrastructure for cost synergies and broader reach.
2. Pain Portfolio as Financial Base
The pain segment, led by Belbuca and Xtampza, provides stable cash flow to fund ADHD expansion and M&A. Belbuca’s formulary wins and profitability offset some erosion from Nucynta generics, but the pain unit’s revenue mix is under pressure. Management is proactively managing loss-of-exclusivity (LOE) risk with authorized generic strategies and settlement agreements to mitigate potential generic competition, particularly for Belbuca in 2027.
3. Disciplined Capital Deployment
Collegium continues to prioritize business development, debt reduction, and opportunistic share repurchases, maintaining a net debt to adjusted EBITDA ratio of 2.1x. The company targets differentiated CNS and rare disease assets, seeking commercial-stage or near-commercial products with long IP tails and U.S. market fit, aiming for $300-500 million peak net sales per asset.
4. Commercial Execution and Integration
The rapid integration of Astaris and expansion of the ADHD sales force (now 190 reps) positions Collegium for a critical Q3-Q4 inflection, as both products are promoted to an expanded HCP target base. The company’s commercial model leverages targeted digital and field tactics, with positive early feedback from prescribers and field reps on the complementary positioning of Jornay PM and Astaris.
Key Considerations
This quarter marks Collegium’s most significant step yet toward portfolio diversification, but also exposes new dependencies and integration challenges as the ADHD franchise becomes the primary growth vector.
Key Considerations:
- ADHD Market Penetration: Sustained prescription growth and high prescriber intent to increase use suggest continued share gains, but competition from established brands remains intense.
- Generic Pricing Pressure: Nucynta’s net price reset is now reflected in guidance, but future pain franchise LOEs (especially Belbuca in 2027) require monitoring.
- Operating Leverage: Incremental SG&A from Astaris is modest, with management signaling mid-to-upper single digit expense growth in H2 to support commercial push.
- M&A Pipeline Discipline: Management reiterates strict criteria for future deals, with CNS and rare disease the clear focus for capital allocation.
Risks
Collegium faces heightened risk from pain franchise patent expirations, with Belbuca’s potential generic entry as early as 2027 if Teva acts on its settlement rights. Further generic price erosion in Nucynta and shifting payer dynamics could weigh on margins. ADHD franchise growth is subject to competitive response, payer formulary shifts, and execution risk as the sales force scales. Integration of acquired assets and realization of cost synergies remain critical to sustaining EBITDA growth.
Forward Outlook
For Q3, Collegium guided to:
- ADHD franchise acceleration as back-to-school season drives prescription volume
- Incremental SG&A investment to support Astaris and Jornay PM commercial activities
For full-year 2026, management updated guidance:
- Total product revenue of $825 to $855 million (8% YoY growth at midpoint)
- Adjusted EBITDA of $445 to $470 million (flat YoY)
- Jornay PM revenue of $190 to $200 million; Astaris revenue of $65 to $75 million
Management highlighted several factors that will shape H2 results:
- Successful execution of ADHD commercial push during back-to-school season
- Stabilized Nucynta generic pricing with no further expected erosion
Takeaways
Collegium’s transformation into a CNS and ADHD-driven company is underway, but the next 18 months will test its ability to offset pain franchise headwinds and scale new assets efficiently.
- ADHD Franchise Shift: The company’s growth narrative now rests on Jornay PM and Astaris, both of which show strong early adoption and prescriber enthusiasm, but require flawless execution to realize their full market potential.
- Pain Portfolio Resilience: While Belbuca and Xtampza provide a steady base, future LOEs and ongoing generic erosion (Nucynta) will challenge margin stability and require continued proactive management.
- Capital Deployment Pathway: Investors should watch for further M&A in CNS and rare disease, as management’s discipline and integration track record will determine long-term value creation.
Conclusion
Collegium’s Q2 results underscore a decisive pivot toward ADHD and CNS, with the Astaris acquisition and Jornay PM growth setting a new trajectory. The pain portfolio’s durability supports this transition, but generic risk and execution in ADHD will be the key determinants of future upside. Investors should monitor the integration pace and upcoming back-to-school demand surge as leading indicators of sustained momentum.
Industry Read-Through
Collegium’s success in rapidly scaling differentiated ADHD assets signals the rising importance of portfolio breadth and commercial agility in specialty pharma. The company’s approach to integrating new brands and leveraging existing sales infrastructure offers a playbook for peers seeking to diversify beyond mature pain franchises. Generic pricing resets in legacy products, as seen with Nucynta, highlight the persistent risk to established brands industry-wide. As CNS and rare disease assets become increasingly attractive, expect heightened competition for commercial-stage deals, with long IP and U.S. market fit as key differentiators. Payers’ role in formulary access remains a critical battleground, especially as ADHD and CNS categories draw more entrants and innovation.